Page last updated: 2024-10-27

flutamide and Carcinoma

flutamide has been researched along with Carcinoma in 33 studies

Flutamide: An antiandrogen with about the same potency as cyproterone in rodent and canine species.

Carcinoma: A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.

Research Excerpts

ExcerptRelevanceReference
"This prospective trial was undertaken to determine the benefits of the combination of bilateral orchidectomy with flutamide, both in terms of survival and quality of life for patients with advanced prostatic carcinoma."9.07The treatment of advanced prostatic carcinoma with total androgenic blockade using bilateral orchidectomy and flutamide: experience at the National Cancer Institute in Mexico. ( De-la-Garza, J; Mendoza-Valdés, A; Ocampo-del-Carpio, O, 1991)
"Little is known about the efficacy of flutamide monotherapy in previously untreated patients with prostatic carcinoma."8.78Flutamide monotherapy as primary treatment in advanced prostatic carcinoma. ( Delaere, KP; Van Thillo, EL, 1991)
"Twelve consecutive men with disseminated prostate carcinoma were evaluated at 0, 6, and 12 months after treatment with a long acting gonadotropin-releasing hormone agonist (goserelin acetate) and an androgen antagonist (flutamide)."7.70The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. ( Bryant, C; Campbell, J; Diamond, T; Lynch, W, 1998)
"A series of 115 previously untreated patients displaying clinical stage C prostatic carcinoma with no evidence of distant metastases received combination therapy using the antiandrogen flutamide and the LHRH agonist [D-Trp6, des-Gly-NH(2)10]LHRH ethylamide; the average follow-up was 3."7.68Combination therapy with flutamide and the LHRH agonist [D-Trp6, des-Gly-NH(2)10]LHRH ethylamide in stage C prostatic carcinoma. ( Cusan, L; Dupont, A; Emond, J; Gomez, JL; Koutsilieris, M; Labrie, F; Suburu, R, 1993)
"To compare the efficacy of orchiectomy alone and orchiectomy plus flutamide in treating patients with advanced carcinoma prostate."5.11Combined androgen blockade in the management of advanced prostate cancer: a sensible or ostensible approach. ( Ansari, MS; Dogra, PN; Gupta, NP; Hemal, AK; Seth, A, 2004)
"Five hundred forty-six patients with advanced loco-regional (M0) or distant metastatic (M1) prostatic carcinoma treated with flutamide combined with either orchiectomy or LHRH analogues were included in this analysis."5.08PSA evolution: a prognostic factor during treatment of advanced prostatic carcinoma with total androgen blockade. Data from a Belgian multicentric study of 546 patients. ( Casselman, J; Derde, MP; Kaufman, L; Mattelaer, J; Oosterlinck, W; Van Velthoven, R, 1997)
"This prospective trial was undertaken to determine the benefits of the combination of bilateral orchidectomy with flutamide, both in terms of survival and quality of life for patients with advanced prostatic carcinoma."5.07The treatment of advanced prostatic carcinoma with total androgenic blockade using bilateral orchidectomy and flutamide: experience at the National Cancer Institute in Mexico. ( De-la-Garza, J; Mendoza-Valdés, A; Ocampo-del-Carpio, O, 1991)
"Little is known about the efficacy of flutamide monotherapy in previously untreated patients with prostatic carcinoma."4.78Flutamide monotherapy as primary treatment in advanced prostatic carcinoma. ( Delaere, KP; Van Thillo, EL, 1991)
"Twelve consecutive men with disseminated prostate carcinoma were evaluated at 0, 6, and 12 months after treatment with a long acting gonadotropin-releasing hormone agonist (goserelin acetate) and an androgen antagonist (flutamide)."3.70The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. ( Bryant, C; Campbell, J; Diamond, T; Lynch, W, 1998)
"05% BBN [N-butyl-N-(4-hydroxybutyl)nitrosamine] orally to 117 Wistar rats for 10 weeks, divided them into seven groups-control, surgical castration, finasteride (2 mg/kg), luteinizing hormone releasing hormone (LH-RH) agonist (1 mg/kg) flutamide (50 mg/kg), LH-RH agonist plus finasteride, and LH-RH agonist plus flutamide-, and then cystectomized them to investigate the incidence of bladder cancer on week 21; experiment 2: we administered 0."3.69Promoting effects and mechanisms of action of androgen in bladder carcinogenesis in male rats. ( Akaza, H; Ami, Y; Ideyama, Y; Imada, S; Koiso, K; Takenaka, T, 1997)
"A series of 115 previously untreated patients displaying clinical stage C prostatic carcinoma with no evidence of distant metastases received combination therapy using the antiandrogen flutamide and the LHRH agonist [D-Trp6, des-Gly-NH(2)10]LHRH ethylamide; the average follow-up was 3."3.68Combination therapy with flutamide and the LHRH agonist [D-Trp6, des-Gly-NH(2)10]LHRH ethylamide in stage C prostatic carcinoma. ( Cusan, L; Dupont, A; Emond, J; Gomez, JL; Koutsilieris, M; Labrie, F; Suburu, R, 1993)
" All patients received hormonal therapy with surgical castration and long-term administration of flutamide."2.67Epirubicin plus flutamide and orchidectomy in previously untreated advanced prostatic cancer. ( Pummer, K, 1991)
"Oxidative stress plays a role in prostate cancer (PrCa) initiation and development."1.37Selenoprotein-P is down-regulated in prostate cancer, which results in lack of protection against oxidative damage. ( Boque, N; Calvo, A; Campion, J; Catena, R; Endermann, T; Gonzalez-Moreno, O; Milagro, F; Redrado, M; Saito, Y; Schomburg, L; Takahashi, K, 2011)
"The numb chin syndrome is characterized by facial numbness along the distribution of the mental branch of the trigeminal nerve."1.31Numb chin syndrome as the presenting symptom of metastatic prostate carcinoma. ( Halachmi, S; Madeb, R; Madjar, S; Nativ, O; River, Y; Wald, M, 2000)
"His suramin therapy was discontinued, but his serum creatinine level continued to rise to 10."1.29Acute renal toxicity associated with suramin in the treatment of prostate cancer. ( Bergan, RC; Cooper, MR; Figg, WD; Headlee, D; Humphrey, J; Reed, E; Sartor, O; Thibault, A, 1994)
"Cancer of the prostate is the most frequent cancer and the second leading cause of cancer death in men in North America."1.29Large Shionogi tumors lose their responsiveness to flutamide treatment. ( Chen, C; Labrie, F; Poulin, R, 1996)
"Lymphangitic carcinomatosis of the lung is a late and often fatal manifestation of cancer."1.28Lymphangitic carcinomas of the lung as presentation of prostatic cancer. A case report. ( Baldelli, S; Cellerino, R; Menichetti, ET; Miseria, S; Murer, B; Torresi, U; Tummarello, D, 1991)

Research

Studies (33)

TimeframeStudies, this research(%)All Research%
pre-19902 (6.06)18.7374
1990's23 (69.70)18.2507
2000's5 (15.15)29.6817
2010's3 (9.09)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Dahlman, A1
Edsjö, A1
Halldén, C1
Persson, JL1
Fine, SW1
Lilja, H1
Gerald, W1
Bjartell, A1
Kawabata, R1
Oie, S1
Oka, T1
Takahashi, M1
Kanayama, H1
Itoh, K1
Gonzalez-Moreno, O1
Boque, N1
Redrado, M1
Milagro, F1
Campion, J1
Endermann, T1
Takahashi, K1
Saito, Y1
Catena, R1
Schomburg, L1
Calvo, A1
Ansari, MS1
Gupta, NP1
Hemal, AK1
Dogra, PN1
Seth, A1
Wang, Y1
Yang, J1
Gao, Y1
Dong, LJ1
Liu, S1
Yao, Z1
Lin, CJ1
Hsieh, RK1
Lim, KH1
Chen, HH1
Cheng, YC1
Wu, CJ1
van der Vange, N1
Greggi, S1
Burger, CW1
Kenemans, P1
Vermorken, JB1
Jindal, PK1
Hota, D1
Prasad, KV1
Nijhawan, R1
Vaidyanathan, S1
Figg, WD1
Cooper, MR1
Thibault, A1
Headlee, D1
Humphrey, J1
Bergan, RC1
Reed, E1
Sartor, O1
Vailancourt, L1
Ttu, B1
Fradet, Y1
Dupont, A3
Gomez, J1
Cusan, L2
Suburu, ER1
Diamond, P1
Candas, B1
Labrie, F4
Bennett, CL1
Matchar, D1
McCrory, D1
McLeod, DG1
Crawford, ED1
Hillner, BE1
Chen, C1
Poulin, R1
Imada, S1
Akaza, H1
Ami, Y1
Koiso, K1
Ideyama, Y1
Takenaka, T1
Boccon-Gibod, L1
Fournier, G1
Bottet, P1
Marechal, JM1
Guiter, J1
Rischman, P1
Hubert, J1
Soret, JY1
Mangin, P1
Mallo, C1
Fraysse, CE1
Oosterlinck, W1
Mattelaer, J1
Casselman, J1
Van Velthoven, R1
Derde, MP1
Kaufman, L1
Denis, LJ2
Keuppens, F2
Smith, PH2
Whelan, P1
de Moura, JL2
Newling, D1
Bono, A2
Sylvester, R2
Yokote, R1
Tokura, Y1
Igarashi, N1
Ishikawa, O1
Miyachi, Y1
Diamond, T1
Campbell, J1
Bryant, C1
Lynch, W1
Gomez, JL1
Koutsilieris, M1
Suburu, R1
Emond, J1
Kirby, R1
Robertson, C1
Turkes, A1
Griffiths, K1
Boyle, P1
Altwein, J1
Schröder, F1
Halachmi, S1
Madeb, R1
Madjar, S1
Wald, M1
River, Y1
Nativ, O1
Matsuda, T1
Junicho, A1
Yamamoto, T1
Kishi, H1
Korkmaz, K1
Saatcioglu, F1
Fuse, H1
Muraguchi, A1
Long, JP1
Prout, GR1
Miseria, S1
Torresi, U1
Menichetti, ET1
Tummarello, D1
Baldelli, S1
Murer, B1
Cellerino, R1
Jurincic, CD1
Horlbeck, R1
Klippel, KF1
Murphy, WM1
Soloway, MS1
Barrows, GH1
Delaere, KP1
Van Thillo, EL1
Mendoza-Valdés, A1
Ocampo-del-Carpio, O1
De-la-Garza, J1
Pummer, K1
Denis, L1
Newling, DW1
Robinson, M1
Mahler, C1
De Pauw, M1
Pavone-Macaluso, M1
Cacciatore, M1
Daricello, G1
Pavone, C1
Serretta, V1
St-Arnaud, R1
Lachance, R1
de Kernion, JN1
Murphy, GP1
Priore, R1

Reviews

1 review available for flutamide and Carcinoma

ArticleYear
Flutamide monotherapy as primary treatment in advanced prostatic carcinoma.
    Seminars in oncology, 1991, Volume: 18, Issue:5 Suppl 6

    Topics: Aged; Aged, 80 and over; Carcinoma; Flutamide; Humans; Male; Middle Aged; Prostatic Neoplasms; Remis

1991

Trials

11 trials available for flutamide and Carcinoma

ArticleYear
Combined androgen blockade in the management of advanced prostate cancer: a sensible or ostensible approach.
    International journal of urology : official journal of the Japanese Urological Association, 2004, Volume: 11, Issue:12

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Carcinoma; Combined Modality Therapy; Flut

2004
Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. A randomized study.
    The American journal of surgical pathology, 1996, Volume: 20, Issue:1

    Topics: Adult; Aged; Androgen Antagonists; Carcinoma; Flutamide; Gonadotropin-Releasing Hormone; Humans; Mal

1996
Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma.
    European urology, 1997, Volume: 32, Issue:4

    Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Carcinoma; Flushing;

1997
PSA evolution: a prognostic factor during treatment of advanced prostatic carcinoma with total androgen blockade. Data from a Belgian multicentric study of 546 patients.
    Acta urologica Belgica, 1997, Volume: 65, Issue:3

    Topics: Aged; Analysis of Variance; Androgen Antagonists; Antineoplastic Agents, Hormonal; Belgium; Carcinom

1997
Maximal androgen blockade: final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center.
    European urology, 1998, Volume: 33, Issue:2

    Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasm

1998
Finasteride in association with either flutamide or goserelin as combination hormonal therapy in patients with stage M1 carcinoma of the prostate gland. International Prostate Health Council (IPHC) Trial Study Group.
    The Prostate, 1999, Jul-01, Volume: 40, Issue:2

    Topics: 5-alpha Reductase Inhibitors; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antin

1999
Combined treatment (goserelin plus flutamide) versus monotherapy (goserelin alone) in advanced prostate cancer: a randomized study.
    Seminars in oncology, 1991, Volume: 18, Issue:5 Suppl 6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Carcinoma; Flutamide; Follow-Up Stu

1991
The treatment of advanced prostatic carcinoma with total androgenic blockade using bilateral orchidectomy and flutamide: experience at the National Cancer Institute in Mexico.
    Seminars in oncology, 1991, Volume: 18, Issue:5 Suppl 6

    Topics: Adult; Aged; Aged, 80 and over; Carcinoma; Combined Modality Therapy; Flutamide; Humans; Male; Mexic

1991
Epirubicin plus flutamide and orchidectomy in previously untreated advanced prostatic cancer.
    Seminars in oncology, 1991, Volume: 18, Issue:5 Suppl 6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Combined Modality Therapy; Epirubicin; Fl

1991
Orchidectomy vs. Zoladex plus flutamide in patients with metastatic prostate cancer. The EORTC GU Group.
    European urology, 1990, Volume: 18 Suppl 3

    Topics: Aged; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Busereli

1990
Comparison of flutamide and Emcyt in hormone-refractory metastatic prostatic cancer.
    Urology, 1988, Volume: 31, Issue:4

    Topics: Anilides; Carcinoma; Clinical Trials as Topic; Estramustine; Flutamide; Hematologic Diseases; Humans

1988

Other Studies

21 other studies available for flutamide and Carcinoma

ArticleYear
Effect of androgen deprivation therapy on the expression of prostate cancer biomarkers MSMB and MSMB-binding protein CRISP3.
    Prostate cancer and prostatic diseases, 2010, Volume: 13, Issue:4

    Topics: Aged; Androgen Antagonists; Biomarkers, Tumor; Carcinoma; Epigenesis, Genetic; Flutamide; Gene Expre

2010
Hydroxyflutamide enhances cellular sensitivity to 5-fluorouracil by suppressing thymidylate synthase expression in bicalutamide-resistant human prostate cancer cells.
    International journal of oncology, 2011, Volume: 38, Issue:3

    Topics: Androgen Antagonists; Anilides; Antimetabolites, Antineoplastic; Carcinoma; Cell Line, Tumor; Drug E

2011
Selenoprotein-P is down-regulated in prostate cancer, which results in lack of protection against oxidative damage.
    The Prostate, 2011, Jun-01, Volume: 71, Issue:8

    Topics: Androgen Antagonists; Carcinoma; Cell Line, Tumor; Cell Transformation, Neoplastic; Down-Regulation;

2011
Reciprocal regulation of 5alpha-dihydrotestosterone, interleukin-6 and interleukin-8 during proliferation of epithelial ovarian carcinoma.
    Cancer biology & therapy, 2007, Volume: 6, Issue:6

    Topics: Androgen Receptor Antagonists; Carcinoma; Cell Line, Tumor; Cell Proliferation; Dihydrotestosterone;

2007
Fatal spontaneous tumor lysis syndrome in a patient with metastatic, androgen-independent prostate cancer.
    Southern medical journal, 2007, Volume: 100, Issue:9

    Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Pr

2007
Experience with hormonal therapy in advanced epithelial ovarian cancer.
    Acta oncologica (Stockholm, Sweden), 1995, Volume: 34, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Carcinoma; Es

1995
Advanced prostatic carcinoma in a 19-year-old male.
    Urologia internationalis, 1994, Volume: 52, Issue:4

    Topics: Adult; Carcinoma; Combined Modality Therapy; Flutamide; Humans; Interferon alpha-2; Interferon-alpha

1994
Acute renal toxicity associated with suramin in the treatment of prostate cancer.
    Cancer, 1994, Sep-01, Volume: 74, Issue:5

    Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Combined Modality Th

1994
Cost-effective models for flutamide for prostate carcinoma patients: are they helpful to policy makers?
    Cancer, 1996, May-01, Volume: 77, Issue:9

    Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Carcinoma; Cost-Benefit Analysis; Disease Pro

1996
Large Shionogi tumors lose their responsiveness to flutamide treatment.
    The Journal of steroid biochemistry and molecular biology, 1996, Volume: 58, Issue:5-6

    Topics: Animals; Antineoplastic Agents, Hormonal; Carcinoma; Cell Division; Flutamide; Humans; Male; Mice; N

1996
Promoting effects and mechanisms of action of androgen in bladder carcinogenesis in male rats.
    European urology, 1997, Volume: 31, Issue:3

    Topics: Administration, Oral; Androgen Antagonists; Animals; Antineoplastic Agents, Hormonal; Antineoplastic

1997
Photosensitive drug eruption induced by flutamide.
    European journal of dermatology : EJD, 1998, Volume: 8, Issue:6

    Topics: Aged; Antineoplastic Agents, Hormonal; Biopsy, Needle; Carcinoma; Dermatitis, Photoallergic; Diagnos

1998
The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy.
    Cancer, 1998, Oct-15, Volume: 83, Issue:8

    Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Amino Acids; Androgen Antagonists; Antineoplastic A

1998
Combination therapy with flutamide and the LHRH agonist [D-Trp6, des-Gly-NH(2)10]LHRH ethylamide in stage C prostatic carcinoma.
    British journal of urology, 1993, Volume: 72, Issue:5 Pt 1

    Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Carcinoma; Drug Ther

1993
Numb chin syndrome as the presenting symptom of metastatic prostate carcinoma.
    Urology, 2000, Volume: 55, Issue:2

    Topics: Aged; Antineoplastic Agents, Hormonal; Biopsy; Carcinoma; Chin; Drug Therapy, Combination; Flutamide

2000
Cross-talk between signal transducer and activator of transcription 3 and androgen receptor signaling in prostate carcinoma cells.
    Biochemical and biophysical research communications, 2001, Apr-27, Volume: 283, Issue:1

    Topics: Androgen Receptor Antagonists; Antineoplastic Agents, Hormonal; Carcinoma; Dihydrotestosterone; DNA-

2001
The usefulness of serum acid phosphatase in monitoring patients with advanced prostate carcinoma.
    Advances in experimental medicine and biology, 1992, Volume: 324

    Topics: Alkaline Phosphatase; Biomarkers, Tumor; Bone Neoplasms; Carcinoma; Cyclophosphamide; Estramustine;

1992
Lymphangitic carcinomas of the lung as presentation of prostatic cancer. A case report.
    Tumori, 1991, Feb-28, Volume: 77, Issue:1

    Topics: Buserelin; Carcinoma; Flutamide; Goserelin; Humans; Lung Neoplasms; Lymphangitis; Male; Middle Aged;

1991
Pathologic changes associated with androgen deprivation therapy for prostate cancer.
    Cancer, 1991, Aug-15, Volume: 68, Issue:4

    Topics: Aged; Androgens; Antineoplastic Agents; Carcinoma; Combined Modality Therapy; Drug Therapy, Combinat

1991
Carcinoma of the prostate. Guidelines for treatment: the role of antiandrogens.
    Annals of the New York Academy of Sciences, 1990, Volume: 595

    Topics: Androgen Antagonists; Carcinoma; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Prostatic Neop

1990
Stimulation of the circulating levels of glycoprotein hormone alpha-subunit after combined administration of a luteinizing hormone-releasing hormone (LHRH) agonist and flutamide in patients with cancer of the prostate.
    Clinical and investigative medicine. Medecine clinique et experimentale, 1986, Volume: 9, Issue:4

    Topics: Androgen Antagonists; Anilides; Carcinoma; Castration; Flutamide; Glycoprotein Hormones, alpha Subun

1986